Flagship Harbor Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

Flagship Harbor Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$72.61 - $90.2 $7,914 - $9,831	-109 Closed	0 $0
Q3 2020 Oct 13, 2020	BUY	$71.87 - $131.03 $1,221 - $2,227	17 Added 18.48%	109 $8,000
Q2 2020 Jul 31, 2020	BUY	$79.55 - $124.22 $7,318 - $11,428	92 New	92 $11,000
Q4 2018 Jan 28, 2019	SELL	$80.14 - $106.07 $20,355 - $26,941	-254 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $19,306 - $25,153	254 New	254 $23,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Flagship Harbor Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Flagship Harbor Advisors, LLC with notifications on news.